Formulation comprising one or more amino acid(s)

Abstract

The invention relates to a formulation comprising one or more amino acid(s), preferably packaged in a sachet.

Description

[0001] Description

[0002] Title of the invention: Formulation comprising one or more amino acid(s)

[0003] [1] The present invention relates to the technical field of food formulations comprising combinations of compounds.

[0004] [2] For the purposes of this description, an interval described by the expression "between [...] and [...]" includes the bounds. For example, the interval "between 1 and 2" includes the two values ​​"1" and "2" as well as all values ​​that are both strictly greater than 1 and strictly less than 2.

[0005] [3] In this description, the term "approximately" preceding a numeric value means that the value can be changed by plus or minus 10%. In the specific case of a numeric value being an interval bound, the term "approximately" means that the lower bound can be increased or decreased by 10% and / or the upper bound can be increased or decreased by 10%. It is also possible to omit the term "approximately" preceding a numeric value.

[0006] [4] Dietary supplements containing amino acids have become popular in recent years due to their essential role in health and general well-being. Amino acids, which are the building blocks of proteins, play a fundamental role in various biological processes, such as muscle building, tissue regeneration, and immune system function.

[0007] [5] Traditionally, they are classified into two categories: essential amino acids, which the body cannot synthesize and must therefore obtain through food, and non-essential amino acids, which the body can produce.

[0008] [6] Among the essential amino acids are leucine, isoleucine and valine, which are particularly prized by athletes for their beneficial effects on physical performance and muscle recovery.

[0009] [7] In addition, some supplements containing amino acids, such as glutamine and creatine, are often used to improve endurance, reduce fatigue, and increase muscle mass. [8] They may also play a role in mental health by influencing neurotransmitter production and helping to regulate mood. The quality of products on the market can vary considerably, making caution necessary when choosing these supplements.

[0010] [9] There are a number of compounds that are important for the functioning of the body.

[0011]

[0010] For example, hyaluronic acid is an essential molecule in the human body, recognized for its many benefits. Naturally present in the skin, joints, and connective tissues, it plays a crucial role in hydration and lubrication. By attracting and retaining water, hyaluronic acid helps maintain the skin's elasticity and firmness, thus reducing the appearance of wrinkles. In the joints, it acts as a shock absorber, facilitating movement and reducing friction. N-Acetyl-Glucosamine is a direct precursor of hyaluronic acid.

[0012]

[0011] For example, collagen is a fundamental protein found in the body, representing approximately 30% of total protein. It is the main component of connective tissues, such as skin, bones, tendons, and cartilage, and plays a crucial role in the structure and strength of these tissues. By providing elasticity and firmness to the skin, collagen helps prevent premature aging and maintain a youthful appearance. In addition, it promotes wound healing and supports joint health by reducing friction.

[0013]

[0012] For example, elastin is an essential protein that provides elasticity and resilience to the connective tissues of the human body, including the skin, blood vessels, and ligaments. Its main function is to allow tissues to return to their original shape after being stretched or contracted. This is particularly crucial in areas such as the skin, where elastin helps maintain firmness and elasticity, thus reducing the appearance of wrinkles and sagging skin. In addition, in blood vessels, it contributes to the regulation of blood pressure. Elastin production decreases with age, highlighting the importance of this protein for maintaining healthy skin and good vascular function.

[0014]

[0013] There is a need for such formulations to promote the endogenous production of such compounds important for the human body.

[0014] In the prior art, a number of studies have been carried out.

[0015]

[0015] Thus, in application WO202306894 filed on behalf of NV NUTRICIA, a spray-drying process is described for manufacturing powders with a high fat content, including nutritional products such as infant formula, growing-up milk, or medical products. These products may contain amino acids.

[0016]

[0016] Furthermore, in application WO202044163 filed on behalf of APR APPLIED PHARMA RESEARCH SA, a solution is described for normalizing amino acid metabolism in individuals following a low-protein diet supplemented with amino acids. The objective is to treat associated metabolic disorders, such as phenylketonuria (PKU), using modified-release formulations of amino acids. This technology is presented as improving nitrogen balance, preventing muscle loss, and stabilizing glucose and insulin levels.

[0017]

[0017] Finally, in application W02016088078 filed on behalf of PROFESSIONAL DIETETICS SPA, compositions based on amino acids (glycine, L-proline, L-alanine, L-valine, L-leucine, and L-lysine) are described. This composition is presented as stimulating the biosynthesis of elastin and collagen, essential for the recovery of fibroelastin in cutaneous connective tissues.

[0018]

[0018] In application KR102226810 filed on behalf of Daewoong Pharmaceutical Co., Ltd., a composition is disclosed which is presented as being intended to promote the biosynthesis of elastin and collagen in connective tissues. This composition is based primarily on a mixture of amino acids associated with a divalent metal ion.

[0019]

[0019] In application CN 113260367, a composition comprising a mixture of amino acids associated with a divalent metal ion, preferably copper, is also described.

[0020]

[0020] In application W02016088078 on behalf of Professional Dietetics SpA, an amino acid-based composition is described as being intended to stimulate the biosynthesis of elastin and collagen in dermal connective tissues.

[0021]

[0021] In application KR20230084390, a composition presented as beneficial for the skin is described, based on a complex of more than 10 amino acids.

[0022] In application US20130108603 filed on behalf of Mark K. Bennett, a formulation including amino acids is disclosed.

[0022]

[0023] Patent KR102585310 describes a cosmetic and nutraceutical composition apparently intended to improve the condition of the skin, notably by means of what is presented as an amino acid complex.

[0023]

[0024] Application AU2023220676 (WO2023158164) on behalf of KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY- ACADEMIC COOPERATION FOUNDATION describes derivatives of amidated amino acids.

[0024]

[0025] Finally, in application US20060161018 on behalf of RIKEN, a composition of amino acids is disclosed, presented as being able to accelerate the burning of body fat.

[0025]

[0026] These formulations are not entirely satisfactory.

[0026]

[0027] Surprisingly, it was discovered by the plaintiff that improved formulations could be made.

[0027]

[0028] The invention relates to a formulation, preferably a food formulation, comprising at least glycine or one of its salts.

[0028]

[0029] In one embodiment, said glycine is not covalently modified.

[0029]

[0030] It has been discovered that glycine deficiency is often a limiting factor for collagen synthesis, and that supplementation can significantly improve this process. Furthermore, it has also been discovered that a high concentration of glycine sustainably stimulates collagen synthesis, particularly for cartilage regeneration.

[0030]

[0031] In one embodiment, the mass percentage of glycine, relative to the total mass of said formulation, is between about 25% and about 75%, preferably between about 30% and about 70%, preferably between about 35% and about 65%, preferably between about 40% and about 60%, preferably between about 45% and about 55%, preferably between about 48% and about 52%, preferably about 51%.

[0032] In one embodiment, said formulation further comprises at least proline or one of its salts, preferably proline or one of its salts, preferably L-proline.

[0031]

[0033] In one embodiment, said proline is not covalently modified.

[0032]

[0034] It has been discovered that proline plays a role in stabilizing collagen fibers, which is useful for tissue regeneration.

[0033]

[0035] In one embodiment, the mass percentage of proline, relative to the total mass of said formulation, is between about 5.0% and about 14.9%, preferably between about 6.0% and about 13.9%, preferably between about 7.0% and about 12.9%, preferably between about 8.0% and about 11.9%, preferably between about 8.9% and about 11.9%, preferably between about 10% and about 11%, preferably about 10.2%.

[0034]

[0036] In one embodiment, said formulation further comprises at least lysine or one of its salts, preferably the acetate salt, preferably L-lysine or one of its salts, preferably L-lysine acetate.

[0035]

[0037] In one embodiment, said formulation further comprises at least lysine or one of its salts, preferably lysine acetate.

[0036]

[0038] In one embodiment, said lysine is not covalently modified.

[0037]

[0039] It has been discovered that lysine is an essential amino acid for the synthesis and strengthening of collagen fibers.

[0038]

[0040] In one embodiment, the mass percentage of lysine, relative to the total mass of said formulation, is between about 5.0% and about 14.9%, preferably between about 6.0% and about 13.9%, preferably between about 7.0% and about 12.9%, preferably between about 8.0% and about 11.9%, preferably between about 8.9% and about 11.9%, preferably between about 10% and about 11%, preferably about 10.2%.

[0039]

[0041] In one embodiment, the mass percentage of lysine, relative to the total mass of said formulation, is between approximately 4% and approximately 11%, preferably between approximately 5% and approximately 10%, preferably between approximately 6% and approximately 9%, preferably between approximately 6% and approximately 8%, preferably approximately 6.1%

[0040]

[0042] In one embodiment, the formulation according to the invention further comprises at least lysine or one of its salts, preferably the acetate salt, preferably L-lysine or one of its salts, preferably L-lysine acetate, preferably at a mass percentage, relative to the total mass of said formulation, of between approximately 4% and approximately 11%, preferably between approximately 5% and approximately 10%, preferably between approximately 6% and approximately 9%, preferably between approximately 6% and approximately 8%, preferably approximately 6.1%

[0041]

[0043] In one embodiment, the formulation according to the invention further comprises at least lysine or one of its salts, preferably lysine acetate, preferably L-lysine acetate, preferably at a mass percentage, relative to the total mass of said formulation, of between approximately 4% and approximately 11%, preferably between approximately 5% and approximately 10%, preferably between approximately 6% and approximately 9%, preferably between approximately 6% and approximately 8%, preferably approximately 6.1%

[0042]

[0044] For the purposes of this description, lysine acetate is preferred. Indeed, it has been shown to result in better stabilization. Without being bound by any technical explanation, it appears to create a more stable microenvironment and limit undesirable reactions in a mixture. Furthermore, it is likely to interact less with vitamin C and reduce browning phenomena (Maillard reaction).

[0043]

[0045] These quantities have been carefully selected to meet the body's needs while also ensuring an adequate amount of lysine is available. Lysine must be added in a higher quantity because it reacts with proline in the formulation, meaning that some lysine will ultimately not be available to meet the body's needs. Therefore, a technical overdose is anticipated.

[0044]

[0046] A synergy has been discovered between glycine, proline and lysine, which guarantees increased production of stable and resistant collagen fibers, thus strengthening the firmness and elasticity of tissues.

[0047] It has been discovered that these amino acids are absorbed very quickly by the body.

[0045]

[0048] This means that once ingested, they quickly enter the bloodstream and are available for the synthesis of compounds important to the human body.

[0046]

[0049] In one embodiment, said formulation further comprises at least vitamin C.

[0047]

[0050] In one embodiment, the vitamin C is coated.

[0048]

[0051] It has been discovered that vitamin C, which is a powerful antioxidant, also plays a key role in collagen synthesis.

[0049]

[0052] In one embodiment, the mass percentage of vitamin C, relative to the total mass of said formulation, is between about 1.2% and about 3.7%, preferably between about 1.5% and about 3.5%, preferably between about 1.7% and about 3.2%, preferably between about 2.0% and about 3.0%, preferably between about 2.2% and about 2.7%, preferably between about 2.4% and about 2.6%, preferably about 2.5%.

[0050]

[0053] In one embodiment, said formulation further comprises at least N-acetyl-D-glucosamine.

[0051]

[0054] In one embodiment, the mass percentage of N-acetyl-D-glucosamine, relative to the total mass of said formulation, is between about 2.5% and about 7.5%, preferably between about 3.0% and about 7.0%, preferably between about 3.5% and about 6.5%, preferably between about 4.0% and about 6.0%, preferably between about 4.5% and about 5.5%, preferably between about 4.8% and about 5.2%, preferably about 5.1%.

[0052]

[0055] It has been discovered that the addition of N-acetyl-D-glucosamine further enhances the effectiveness of the synergy mentioned above, by promoting the synthesis of collagen and hyaluronic acid.

[0053]

[0056] In one embodiment, said formulation further comprises at least zinc or one of its salts, preferably zinc gluconate.

[0054]

[0057] In one embodiment, said formulation further comprises at least zinc or one of its salts, preferably zinc bisglycinate.

[0058] It has been discovered that zinc is important for collagen production and protecting cells against free radicals.

[0055]

[0059] In one embodiment, the mass percentage of zinc, relative to the total mass of said formulation, is between about 0.3% and about 0.9%, preferably between about 0.3% and about 0.8%, preferably between about 0.4% and about 0.8%, preferably between about 0.5% and about 0.7%, preferably between about 0.5% and about 0.6%.

[0056]

[0060] In one embodiment, said formulation further comprises at least glutamine or one of its salts, preferably L-glutamine.

[0057]

[0061] In one embodiment, said glutamine is not covalently modified.

[0058]

[0062] It has been discovered that glutamine enables the repair and maintenance of tissues, particularly muscles and skin.

[0059]

[0063] In one embodiment, the mass percentage of glutamine, relative to the total mass of said formulation, is between about 5.0% and about 15.0%, preferably between about 6.0% and about 14.0%, preferably between about 7.0% and about 13.0%, preferably between about 8.0% and about 12.0%, preferably between about 9.0% and about 11.0%, preferably between about 9.6% and about 10.4%, preferably about 10.2%.

[0060]

[0064] In one embodiment, said formulation further comprises at least arginine or one of its salts, preferably arginine hydrochloride, arginine base or arginine alpha-ketoglutarate, preferably L-arginine hydrochloride, L-arginine base or L-arginine alpha-ketoglutarate, preferably L-arginine base or L-arginine alpha-ketoglutarate, preferably L-arginine base.

[0061]

[0065] In one embodiment, said arginine is not covalently modified.

[0062]

[0066] It has been discovered that arginine promotes blood circulation and collagen production, and plays a role in tissue healing and repair.

[0063]

[0067] In one embodiment, the mass percentage of arginine, relative to the total mass of said formulation, is between about 3.5% and about 10.6%, preferably between about 4.3% and about 9.9%, preferably between about 5.0% and about 9.2%, preferably between about 5.7% and about 8.5%, preferably between about 6.4% and about 7.8%, preferably between about 6.8% and about 7.4%, preferably about 7.2%.

[0064]

[0068] In one embodiment, the mass percentage of arginine, relative to the total mass of said formulation, is between about 3% and about 11%, preferably between about 4% and about 10%, preferably between about 5% and about 9%, preferably between about 6% and about 8%, preferably about 7.3%.

[0065]

[0069] These quantities have been carefully selected to meet the body's needs while also ensuring an adequate amount of arginine is available. Indeed, arginine must be added in a higher quantity because it reacts with proline in the formulation, meaning that some arginine will ultimately not be available to meet the body's needs. Therefore, a technical overdose is anticipated.

[0066]

[0070] It has been discovered that arginine is also absorbed very rapidly by the body. This means that once ingested, it quickly enters the bloodstream and is available for the synthesis of compounds important to the human body.

[0067]

[0071] Furthermore, it is known that arginine is difficult to formulate with lysine, even though these two amino acids are crucial for formulation efficacy. Surprisingly, it has been discovered that a selection of specific forms of these amino acids makes them compatible in terms of formulation.

[0068]

[0072] Thus, L-lysine acetate was selected, and L-arginine base was also specifically chosen. This is therefore a preferred embodiment.

[0069]

[0073] In a similarly preferred embodiment, the formulation according to the invention is characterized in that it comprises L-arginine hydrochloride and L-lysine acetate.

[0070]

[0074] In this case, arginine is present as L-arginine hydrochloride, and lysine is present as L-lysine acetate. These compounds have been shown to be particularly compatible.

[0075] Indeed, it has been shown that when lysine is present in the form of L-lysine acetate, then L-arginine is as effective in the form of L-arginine hydrochloride as in the form of L-arginine base.

[0071]

[0076] Accordingly, in an overall preferred embodiment, the formulation according to the invention is characterized in that it comprises L-arginine hydrochloride or L-arginine base, and L-lysine acetate.

[0072]

[0077] In one embodiment, the formulation according to the invention is characterized in that it comprises L-arginine hydrochloride or L-arginine base, preferably at a mass percentage, relative to the total mass of said formulation, of between approximately 3.5% and approximately 10.6%, preferably between approximately 4.3% and approximately 9.9%, preferably between approximately 5.0% and approximately 9.2%, preferably between approximately 5.7% and approximately 8.5%, preferably between approximately 6.4% and approximately 7.8%, preferably between approximately 6.8% and approximately 7.4%, preferably approximately 7.2%, and L-lysine acetate, preferably at a mass percentage, relative to the total mass of said formulation, of between approximately 5.0% and approximately 14.9%, preferably between approximately 6.0% and approximately 13.9%, preferably between approximately 7.0% and approximately 12.9%, preferably between approximately 8.0% and approximately 11.9%, preferably between approximately 8,9% and approximately 11.9%, preferably between approximately 10% and approximately 11%, preferably approximately 10.2%.

[0073]

[0078] These compounds are compatible and allow for formulation optimization.

[0074]

[0079] The synergy mentioned above is supported and enhanced by the presence of vitamin C, N-acetyl-D-glucosamine, zinc, glutamine and arginine, which optimize the synthesis process and protect cells against oxidative stress.

[0075]

[0080] A number of excipients may also be added.

[0076]

[0081] In one embodiment, said formulation further comprises at least one flavor, preferably pineapple flavor, preferably having a mass percentage, relative to the total mass of said formulation, of between about 1.6% and about 4.7%, preferably between about 1.9% and about 4.3%, preferably between about 2.2% and about 4.0%, preferably between about 2.5% and about 3.7%, preferably between about 2.8% and about 3.4%, preferably between about 3.0% and about 3.2%.

[0077]

[0082] In one embodiment, said formulation further comprises at least one stabilizer, preferably maltodextrin or acacia fibers.

[0078]

[0083] In one embodiment, said formulation further comprises at least one stabilizer, preferably maltodextrin, preferably having a mass percentage, relative to the total mass of said formulation, of between about 1.2% and about 3.5%, preferably between about 1.4% and about 3.3%, preferably between about 1.6% and about 3.1%, preferably between about 1.9% and about 2.8%, preferably between about 2.1% and about 2.6%, preferably between about 2.3% and about 2.4%.

[0079]

[0084] In one embodiment, said formulation further comprises at least one stabilizer, preferably acacia fiber, preferably having a mass percentage, relative to the total mass of said formulation, of between about 1.2% and about 3.5%, preferably between about 1.4% and about 3.3%, preferably between about 1.6% and about 3.1%, preferably between about 1.9% and about 2.8%, preferably between about 2.1% and about 2.6%, preferably between about 2.3% and about 2.4%.

[0080]

[0085] Humidity can cause powders, especially hydrophilic amino acids like L-glutamine, to clump. It has generally been found that including maltodextrin helps ensure a smooth and homogeneous texture.

[0081]

[0086] In one embodiment, said formulation further comprises at least one sweetener, preferably steviol glycosides from Stevia, preferably having a mass percentage, relative to the total mass of said formulation, of between about 0.1% and about 0.3%, preferably between about 0.1% and about 0.3%, preferably between about 0.1% and about 0.3%, preferably about 0.2%.

[0082]

[0087] In one embodiment, said formulation further comprises at least one preservative, preferably citric acid, preferably having a mass percentage, relative to the total mass of said formulation, of between about 0.1% and about 0.3%, preferably between about 0.1% and about 0.3%, preferably between about 0.1% and about 0.3%, preferably about 0.2%.

[0083]

[0088] In one embodiment, said formulation further comprises at least one colorant, preferably beta-carotene, preferably having a mass percentage, relative to the total mass of said formulation, of between about 0.1% and about 0.3%, preferably between about 0.1% and about 0.2%.

[0084]

[0089] In one embodiment, said formulation further comprises at least one colorant, preferably beta-carotene, preferably having a mass percentage, relative to the total mass of said formulation, of between about 0.01% and about 0.05%, preferably between about 0.02% and about 0.04%, preferably about 0.03%.

[0085]

[0090] In one embodiment, said formulation further comprises at least one first emulsifier, preferably sucrose esters of fatty acids, preferably having a mass percentage, relative to the total mass of said formulation, of between about 0.1% and about 0.2%.

[0086]

[0091] It has been discovered that sucrose esters of fatty acids help to ensure better absorption of active ingredients.

[0087]

[0092] In one embodiment, said formulation further comprises at least one second emulsifier, preferably sunflower lecithin, preferably having a mass percentage, relative to the total mass of said formulation, of between about 0.04% and about 0.1%, preferably between about 0.05% and about 0.1%, preferably between about 0.06% and about 0.1%, preferably between about 0.07% and about 0.1%, preferably between about 0.08% and about 0.1%, preferably between about 0.08% and about 0.09%, preferably about 0.09%.

[0088]

[0093] In one embodiment, said formulation further comprises at least one thickener, preferably guar gum, preferably having a mass percentage, relative to the total mass of said formulation, of between about 0.07% and about 0.22%, preferably between about 0.88% and about 0.21%, preferably between about 0.10% and about 0.19%, preferably between about 0.12% and about 0.18%, preferably between about 0.13% and about 0.16%, preferably between about 0.14% and about 0.15%, preferably about 0.15%.

[0094] Surprisingly, it has been discovered that guar gum allows for a prolonged release of active ingredients.

[0089]

[0095] In one embodiment, the formulation is presented in a form chosen from the group consisting of tablets, capsules, powders in sachets, liquids, sprays, energy bars, candies, infusions, dissolvable plates or films, jellies, syrups, ampoules, lozenges and gums.

[0090]

[0096] In one embodiment, the formulation is in the form of a powder in a sachet.

[0091]

[0097] In one embodiment, the quantity of powder in a sachet is between approximately 1 g and approximately 30 g, preferably between approximately 2 g and approximately 25 g, preferably between approximately 5 g and approximately 20 g, preferably between approximately 5 g and approximately 15 g, preferably between approximately 6 g and approximately 14 g, preferably between approximately 7 g and approximately 13 g, preferably between approximately 8 g and approximately 12 g, preferably between approximately 9 g and approximately 11 g, preferably approximately 10 g.

[0092]

[0098] In one embodiment, the formulation is vegan.

[0093]

[0099] In one embodiment, the formulation does not include any ingredient of animal origin.

[0094]

[0100] The invention also relates to the use of the formulation according to the invention to provide selected beneficial effects from the group consisting of reducing joint pain, improving joint mobility, regenerating cartilage, reducing stiffness, improving fluidity of movement, reducing pain related to physical exertion, improving hydration of the skin, hair and nails, eliminating back pain, increasing energy, improving skin firmness and appearance, reducing wrinkles, strengthening nails, reducing fatigue, increasing recovery after exertion, reducing skin imperfections, evening out skin tone, increasing skin tone, reducing hair loss, improving hair thickness, and improving mood.reduction of stiffness after training, improved productivity, reduced use of painkillers, and improved sleep quality.

[0095]

[0101] The invention also relates to the formulation according to the invention, preferably in the form of a powder, preferably packaged in a sachet.

[0096]

[0102] In one embodiment, the formulation according to the invention is intended to be administered twice per nyctomer.

[0097]

[0103] The invention also relates to a method of substituting lysine hydrochloride with lysine acetate to obtain a formulation according to the invention.

[0098]

[0104] The invention also relates to a method of substituting L-lysine hydrochloride with L-lysine acetate to obtain a formulation according to the invention.

[0099]

[0105] Example 1: Formulation according to the invention

[0100]

[0106] Examples of formulations according to the invention are given in the tables below:

[0101] [Table 1]

[0102] [Table 2]

[0103] Table 2: Formulation 2 according to the invention

[0104] [Table 3]

[0105]

[0106] Table 3: Formulation 3 according to the invention

[0107] [Table 4] [Table 5]

[0108] Table 5: Formulation 5 according to the invention

[0109] [Table 6]

[0110]

[0111]

[0112] Table 8: Formulation 8 according to the invention

[0113]

[0107] Example 2: Effects of a formulation according to the invention (clinical cases)

[0114]

[0108] All the following clinical cases correspond to the following management: administration of the formulation given in example 1 formulation 8 table 8, twice a day.

[0115]

[0109] Clinical Case 01: MK, 50 years old, suffering from stiffness and joint pain in his knees and wrists, associated with moderate chronic symptoms. MK reports more pronounced pain in the morning and after physical exertion. MK leads an active life with moderate physical activity, although he has limited his movements due to joint pain.

[0116]

[0110] Objective of treatment: MK started taking the dietary supplement with the aim of reducing her joint pain, improving the mobility of her joints and promoting cartilage regeneration.

[0117]

[0111] Effects observed after 10 days of use: From the 10th day, MK reported a significant reduction in joint pain, particularly in the knees. Morning stiffness was significantly reduced, and he experienced greater fluidity in his daily movements. Pain related to physical exertion also decreased, allowing him to gradually resume some activities he had previously limited.

[0118]

[0112] Effects observed after 1 month of use: MK reported that joint pain was significantly reduced and that his mobility had considerably improved. He was able to resume moderate physical activities without experiencing significant pain. Morning pain became rare, indicating improved joint flexibility. Although his primary objective was the reduction of joint pain, MK also noted an improvement in the quality of his skin, with better hydration, his hair, and a reduction in brittle nails.

[0119]

[0113] Clinical case 02: MB, 44 years old, bus driver, suffering from back pain due to prolonged sitting. Not very athletic, he wanted to reduce his back pain and improve his daily comfort.

[0120]

[0114] Objective of the treatment: To relieve her back pain, which was frequent due to her prolonged sitting posture in her job.

[0121]

[0115] Effects observed after 1 week: MB felt the first positive effects on his back, with a reduction in pain.

[0122]

[0116] Effects observed after 3 weeks: Back pain completely disappeared. He felt a boost of energy. His skin became firmer and his wrinkles diminished. His nails became smoother and visibly more beautiful, and his hair was fuller and healthier.

[0123]

[0117] Clinical case 03: ME, 38 years old, no major problems, but wanted to maintain the quality of her skin.

[0124]

[0118] Objective of the treatment: To maintain good skin health and prevent visible signs of aging.

[0125]

[0119] Effects observed after 1 month: ME noticed a marked improvement in the quality of his skin. It became firmer, more hydrated, and overall more radiant. He also noticed a reduction in minor imperfections, making his skin more even-toned. In addition to the effects on the skin, ME observed an unexpected result, namely a noticeable reduction in fatigue.

[0126]

[0120] Clinical case 04: MG, 48 years old, tile setter for 32 years. Back pain and joint stiffness.

[0127]

[0121] Objective of the treatment: To relieve back pain and joint stiffness.

[0128]

[0122] Effects observed after 10 days: MG experienced a marked improvement in his joints, particularly in his back. Stiffness decreased significantly.

[0123] Effects observed after 1 month: MG noticed an even more marked improvement in his joint mobility. His back pain was further reduced. MG also experienced an unexpected increase in energy, a visible reduction in his wrinkles, and firmer skin. He also noted that his nails, often damaged by his manual labor, became stronger and less prone to breakage.

[0129]

[0124] Clinical case 05: ML, 69 years old, suffered from joint problems in his hips and knees, which limited his daily mobility, especially when he had to climb stairs.

[0130]

[0125] Objective of the treatment: To reduce joint pain and improve mobility, particularly for going up and down stairs.

[0131]

[0126] Effects observed after 1 month of use: ML noticed a significant improvement in his mobility. He was able to climb stairs without experiencing discomfort or pain, an activity that had previously been difficult for him. ML also felt a boost in energy, feeling more dynamic and active in his daily activities. In addition to the beneficial effects on his joints and energy levels, ML found the taste of the formulation pleasant, which facilitated its regular use. ML also noticed an improvement in the appearance of his skin. His wrinkles were less pronounced and his skin appeared firmer, a benefit he had not expected when starting the treatment.

[0132]

[0127] Clinical Case 06: Mrs. C., 45 years old, with loss of skin firmness, the appearance of wrinkles, and brittle nails. Mrs. C. is an active woman, a senior executive in a large company, and a regular marathon runner. Despite her healthy lifestyle, she was experiencing signs of skin aging and problems with brittle nails.

[0133]

[0128] Objective of the treatment: To improve the appearance of her skin and strengthen her nails, with very specific "beauty" objectives: reduction of wrinkles, firmer skin, and stronger nails.

[0134]

[0129] Effects observed after 1 month of use: Ms. C. noticed a significant improvement in her skin's firmness. Wrinkles, particularly around the eyes and mouth, became less visible. Her skin appeared more toned, and she reported an overall feeling of hydration and skin vitality. Ms. C. also observed that her nails had become stronger and less brittle, with a marked reduction in breakage. Although this was not her initial objective, Ms. C. was pleasantly surprised to find an improvement in her joint mobility, particularly after her intensive marathon training sessions. She experienced a reduction in joint stiffness, which allowed her to recover better after exertion and continue her sporting activity with greater comfort. Ms. C. also noticed an improvement in her overall physical fitness. She felt more energetic in her daily activities and less tired.

[0135]

[0130] Clinical case 07: Mrs. D., 82, severe osteoarthritis with frequent joint pain, stiffness and limited mobility.

[0136]

[0131] Objective of the treatment: To reduce pain related to her osteoarthritis and improve her mobility.

[0137]

[0132] Effects observed after 1 week of use: Ms. D. noticed a significant reduction in joint pain. She reported that her pain was less frequent and less intense.

[0138]

[0133] Effects observed after 1 month of use: Mrs. D. noticed a significant improvement in her mobility.

[0139]

[0134] Clinical case 08: Mrs. F., 58, wished to improve the elasticity and firmness of her skin.

[0140]

[0135] Objective of the treatment: To improve the elasticity and firmness of the skin, and to reduce visible wrinkles.

[0141]

[0136] Effects observed after 1 month of use: Ms. F. noticed a significant reduction in her wrinkles. Her skin became firmer and more supple, and she felt a visible increase in elasticity, particularly around her eyes and mouth. In addition to the effects on her skin, Ms. F. also noticed an unexpected improvement in her energy levels. She felt less tired on a daily basis and more dynamic in her professional and personal activities. Ms. F. also noticed that she was losing much less hair than before and that her hair seemed to be getting thicker. This unexpected result was particularly appreciated because she had been experiencing hair loss before starting the treatment.

[0142]

[0137] Clinical Case 09: Mrs. H., 46 years old, menopausal, suffered from signs of skin aging, including a loss of skin elasticity, and experienced a general decline in her well-being.

[0138] Objective of treatment: To improve the appearance of her skin and restore better general well-being.

[0143]

[0139] Effects observed after 1 month of use: Ms. H. noticed a significant improvement in the firmness and elasticity of her skin. The signs of skin aging diminished, and her skin became smoother and more hydrated. Ms. H. also observed an improvement in her overall well-being. She felt more energetic, with a more stable mood and better physical fitness.

[0144]

[0140] Clinical case 10: Mrs. J., 34 years old, a very active and stressed woman, wished to prolong her youth and preserve the quality of her skin, hair, and nails.

[0145]

[0141] Objective of treatment: To maintain a youthful appearance, while improving the health of her skin, hair, nails, and joints. She also sought to reduce the effects of stress on her overall well-being.

[0146]

[0142] Effects observed after 1 month of use: Ms. J. observed a gradual improvement in the quality of her skin, which became smoother, firmer, and more hydrated. Her hair was also stronger and shinier, and her nails less brittle. Ms. J. also experienced a noticeable improvement in her joint health, particularly during her daily physical activities. She also noticed a reduction in stress and an improved overall mood, feeling more balanced and energetic.

[0147]

[0143] Clinical case 11: Mrs. K., 42 years old, wished to reduce her wrinkles, mainly around the eyes and mouth, to regain a more youthful appearance.

[0148]

[0144] Objective of the treatment: To reduce wrinkles and regain a more youthful appearance, without resorting to invasive methods.

[0149]

[0145] Effects observed after 1 month of use: Ms. K. noticed a significant reduction in her wrinkles. The skin around her eyes and mouth became smoother, and her complexion more radiant. She was very satisfied with the results achieved in such a short time. Ms. K. also experienced a noticeable reduction in fatigue. She felt more energetic on a daily basis, which further reinforced her positive impression of the food supplement. She also greatly enjoyed the pineapple flavor of the formula.

[0150]

[0146] Example 3: Lysine inclusion and stability

[0147] The following two formulations were prepared.

[0151] [Table 2]

[0152] Table 2: Comparative formulations

[0153]

[0148] Formulation 1 comprises L-Lysine hydrochloride, while formulation 2 comprises L-Lysine acetate

[0154]

[0149] The stability of these formulations has been studied.

[0155]

[0150] The observations concerning formulation 1 are as follows: After only a few days of storage, a significant browning of the powder was observed, as well as a tendency to agglomerate;

[0156] During the test at 40°C and 75% humidity for 30 days, color changes and agglomeration of the powder were observed, the pH also decreased, suggesting an acidic reaction in the mixture.

[0157]

[0151] The same tests were applied to formulation 2, and the latter proved to be perfectly stable. No browning or agglomeration was observed, and pH stability was maintained throughout the test.

[0158]

[0152] In conclusion, the substitution of L-Lysine hydrochloride by L-Lysine acetate results in a drastic improvement in stability.

[0159]

[0153] Finally, without wishing to be bound by any technical explanation, it seems that L-lysine hydrochloride is particularly incompatible with L-proline.

[0160]

[0154] Furthermore, it should be noted that other tests have also demonstrated that a formulation according to the invention, for example according to Example 1, is, all other things being equal, more stable using L-arginine base than using L-arginine hydrochloride, except when L-lysine is present in the form of L-lysine acetate.

Claims

Demands

1. Formulation, preferably food formulation, comprising at least glycine or one of its salts, preferably at a mass percentage, relative to the total mass of said formulation, of between 25% and 75%, preferably between 30% and 70%, preferably between 35% and 65%, preferably between 40% and 60%, preferably between 45% and 55%, preferably between 48% and 52%, preferably 51%.

2. Formulation according to claim 1, characterized in that it further comprises at least proline or one of its salts, preferably proline or one of its salts, preferably L-proline, preferably at a mass percentage, relative to the total mass of said formulation, of between 5.0% and 14.9%, preferably between 6.0% and 13.9%, preferably between 7.0% and 12.9%, preferably between 8.0% and 11.9%, preferably between 8.9% and 11.9%, preferably between 10% and 11%, preferably 10.2%.

3. Formulation according to any one of the preceding claims, characterized in that it further comprises at least lysine or one of its salts, preferably lysine acetate, preferably L-lysine acetate.

4. Formulation according to any one of the preceding claims, characterized in that it further comprises at least vitamin C, preferably at a mass percentage, relative to the total mass of said formulation, of between 1.2% and 3.7%, preferably between 1.5% and 3.5%, preferably between 1.7% and 3.2%, preferably between 2.0% and 3.0%, preferably between 2.2% and 2.7%, preferably between 2.4% and 2.6%, preferably 2.5%.

5. Formulation according to any one of the preceding claims, characterized in that it further comprises at least N-acetyl-D-glucosamine, preferably at a mass percentage, relative to the total mass of said formulation, of between 2.5% and 7.5%, preferably between 3.0% and 7.0%, preferably between 3.5% and 6.5%, preferably between 4.0% and 6.0%, preferably between 4.5% and 5.5%, preferably between 4.8% and 5.2%, preferably 5.1%. Tl

6. Formulation according to any one of the preceding claims, characterized in that it further comprises at least zinc or one of its salts, preferably at a mass percentage, relative to the total mass of said formulation, of between 0.3% and 0.9%, preferably between 0.3% and 0.8%, preferably between 0.4% and 0.8%, preferably between 0.5% and 0.7%, preferably between 0.5% and 0.6%.

7. Formulation according to any one of the preceding claims, characterized in that it further comprises at least some glutamine or one of its salts, preferably L-glutamine, preferably at a mass percentage, relative to the total mass of said formulation, of between 5.0% and 15.0%, preferably between 6.0% and 14.0%, preferably between 7.0% and 13.0%, preferably between 8.0% and 12.0%, preferably between 9.0% and 11.0%, preferably between 9.6% and 10.4%, preferably 10.2%.

8. Formulation according to any one of the preceding claims, characterized in that it further comprises at least some arginine or one of its salts, preferably arginine hydrochloride, arginine base or arginine alpha-ketoglutarate, preferably L-arginine hydrochloride, L-arginine base or L-arginine alpha-ketoglutarate, preferably L-arginine base or L-arginine alpha-ketoglutarate, preferably L-arginine base.

9. A formulation according to any one of the preceding claims, characterized in that it further comprises at least one flavoring, preferably pineapple flavoring, preferably at a mass percentage, relative to the total mass of said formulation, of between 1.6% and 4.7%, preferably between 1.9% and 4.3%, preferably between 2.2% and 4.0%, preferably between 2.5% and 3.7%, preferably between 2.8% and 3.4%, preferably between 3.0% and 3.2%, or in that it further comprises at least one stabilizer, preferably at a mass percentage, relative to the total mass of said formulation, of between 1.2% and 3.5%, preferably between 1.4% and 3.3%, preferably between 1.6% and 3.1%, preferably between 1.9% and 2.8%, preferably between 2.1% and 2.6%, preferably between 2.3% and 2.4%, or in that it further comprises at least one sweetener,preferably steviol glycosides from Stevia, preferably at a mass percentage, relative to the total mass of said formulation, of between 0.1% and 0.3%, preferably of, 0.2%, or in that it further comprises at least one preservative, preferably citric acid, preferably at a mass percentage, relative to the total mass of said formulation, of between 0.1% and 0.3%, preferably 0.2%, or in that it further comprises at least one colorant, preferably beta-carotene.

10. Formulation according to any one of the preceding claims, in the form of a powder, preferably packaged in a sachet.

Images